Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder

Paner, Gladell P.; Annaiah, Chandrakanth; Gulmann, Christian; Rao, Priya; Ro, Jae Y.; Hansel, Donna E.; Shen, Steven S.; López-Beltrán, Antonio; Aron, Manju; Luthringer, Daniel; Peralta‐Venturina, Mariza de; Cho, Yong; Amin, Mahul B.

doi:10.1016/j.humpath.2014.02.024

Cited by 112 publications

(86 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 GATA3 has been proposed as a relatively sensitive and specific immunohistochemical (IHC) marker for urothelial, breast, and parathyroid carcinomas. [9][10][11][12][13][14][15] Relatively small studies looking at GATA3 expression in other tumor types revealed frequent positivity in paragangliomas, salivary gland tumors, ovarian Brenner tumors, and signet ring cell adenocarcinomas of the urinary bladder. 16,17 Less common expression has been documented in renal cell carcinomas, endometrial adenocarcinomas, and squamous cell carcinomas from the head/neck, lung, and cervix.…”

mentioning

confidence: 99%

GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract

Howitt

Emori

Drapkin

et al. 2015

American Journal of Surgical Pathology

136

View full text Add to dashboard Cite

GATA3 is a transcription factor critical for embryogenesis, development, and cell differentiation. Recent studies have suggested that GATA3 is a sensitive and relatively specific biomarker for urothelial and breast carcinomas, with most Müllerian carcinomas being negative. We investigated GATA3 expression in mesonephric/Wolffian remnants and tumors in the female genital tract. A western blot was performed to assess specificity for the GATA3 antibody. GATA3 immunohistochemistry was performed on 59 formalin-fixed paraffin-embedded mesonephric samples, including 17 mesonephric remnants (MR; 11 cervical and 6 fallopian tube), 15 mesonephric hyperplasias, 21 mesonephric carcinomas, and 6 female adnexal tumors of probable Wolffian origin. Thirty conventional endocervical adenocarcinomas (ENDO-CA), 9 gastric-type cervical adenocarcinomas, and 165 endometrial adenocarcinomas (EM-CA) were also evaluated. GATA3 nuclear intensity and extent of staining was evaluated. The western blot revealed GATA3 expression in seminal vesicle and cell lines derived from breast and urothelial carcinomas, but not in other cell lines including ovarian, cervical, and endometrial cancers. All cervical MRs and mesonephric hyperplasias, 5/6 (83%) fallopian tube MRs, and 20/21 (95%) mesonephric carcinomas were GATA3 positive, although with great variability in both intensity (weak to strong) and extent (1+ to 3+) of staining. Only 1/6 (17%) female adnexal tumors of probable Wolffian origin showed weak multifocal staining. One of 30 (3%) usual-type ENDO-CAs and 3/165 EM-CAs exhibited weak-moderate GATA3 immunoreactivity; all gastric-type cervical adenocarcinomas were negative. GATA3 is a highly sensitive and specific marker for mesonephric lesions in the lower genital tract; however, its utility in the upper genital tract may be more limited. In addition, GATA3 can aid in distinguishing lower genital mesonephric lesions from usual-type and gastric-type ENDO-CAs and uterine EM-CAs.

show abstract

mentioning

confidence: 99%

GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract

Howitt

Emori

Drapkin

et al. 2015

American Journal of Surgical Pathology

136

View full text Add to dashboard Cite

show abstract

“…Recent studies have reported that GATA 3 levels in MPV urothelial carcinoma are similar to levels in pure urothelial carcinoma (14). Interestingly, while GATA 3 levels are similar between MPV and pure urothelial carcinoma, GATA 3 levels have been reported to be significantly lower in other variants of urothelial carcinoma such as squamous differentiation variant and sarcomatoid variant (14,15). The reason for this difference is unclear but is likely more reflective of changes in the squamous differentiation variant.…”

Section: Immunohistochemical Evaluationmentioning

confidence: 96%

“…Wang et al recently reported that the presence of p63 was an independent predictor of worse survival in patients with urothelial carcinoma who underwent radical cystectomy with urinary diversion (16). Despite the majority of patients with pure urothelial carcinoma displaying expression of p63, recent studies have reported decreased p63 expression in patients with MPV, with between 27% and 54% of MPV tumors staining positive for p63 (15,17).…”

Section: Immunohistochemical Evaluationmentioning

confidence: 99%

Evolving concepts of micropapillary variant urothelial carcinoma

Monn

Liu²

2016

Transl. Cancer Res.

View full text Add to dashboard Cite

Micropapillary variant (MPV) urothelial carcinoma remains an uncommon, challenging to treat entity. Recent research has emerged that examines the genetic expression profile of MPV urothelial carcinoma and provides a new perspective on this challenging to treat form of bladder cancer. Ongoing research is necessary to determine the most appropriate treatment algorithms for managing patients with MPV urothelial carcinoma.

show abstract

“…G. Paner и соавт. [39] показали, что в недифференцированных карциномах (лимфоэпителиомоподобной, мелкоклеточной и сарко-моподобной) выявлялись: GATA3 -28% случаев, S100P -31%, уроплакин III -0%, тромбомодулин -22%, CK7 -50%, CK20 -3%, p63 -50% и HMCK -49%. Экспрес-сия S100Р и p63 была выражена в 70% лимфоэпителиомо-подобных карцином.…”

Section: архив патологии 4 2015unclassified

“…Сходные данные получены в двух других исследованиях, где лишь 9% LELC экспрес-сировали CK20 [41][42][43]. Показано, что GATA3, S100P, CK7, CK20, HMCK и p63 могут быть включены в диагно-стическую панель для подтверждения уротелиального происхождения морфологических вариантов переходно-клеточного рака МП [39].…”

Section: архив патологии 4 2015unclassified

Lymphoepithelioma-like tumors: A review of literature and a clinical case of bladder carcinoma

2015

View full text Add to dashboard Cite

Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder

Cited by 112 publications

References 56 publications

GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract

GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract

Evolving concepts of micropapillary variant urothelial carcinoma

Lymphoepithelioma-like tumors: A review of literature and a clinical case of bladder carcinoma

Contact Info

Product

Resources

About